Additionally, the combination of AdV5-CCL5 treatment with anti-PD1 in a subcutaneous, B16-HER2 mouse model demonstrated a significant decrease in tumor growth, compared to therapy alone [221]. This evidence concerns the gene ERBB2 and neoplasm.